Wixela is NOT for Cystic Fibrosis
Wixela (fluticasone propionate/salmeterol) is an inhaled corticosteroid/long-acting beta-agonist combination indicated for asthma and COPD—it has no role in treating cystic fibrosis. You are confusing Wixela with ivacaftor (Kalydeco), which is a completely different medication used for CF.
Critical Distinction
Wixela 1:
- Contains fluticasone propionate (inhaled corticosteroid) + salmeterol (LABA)
- FDA-approved for asthma (age ≥4 years) and COPD maintenance
- Works by reducing airway inflammation and bronchodilation
- Has NO activity on CFTR protein defects
Ivacaftor (what you likely meant):
- A CFTR potentiator that corrects the underlying defect in CF
- Specifically targets certain CFTR mutations
CF Foundation Guidelines on Inhaled Corticosteroids
For patients with CF without asthma or allergic bronchopulmonary aspergillosis, the CF Foundation strongly recommends AGAINST routine use of inhaled corticosteroids to improve lung function, quality of life, or reduce pulmonary exacerbations (Grade D recommendation, high certainty of zero to negative benefit) 2.
This means Wixela would be contraindicated in typical CF patients unless they have concurrent asthma as a separate diagnosis.
If You Meant Ivacaftor for CF
For CF patients aged ≥6 years with at least one G551D CFTR mutation, ivacaftor 150 mg orally twice daily is strongly recommended with high certainty of substantial benefit 2.
Ivacaftor Dosing by Age:
- Ages 12+ years and adults: 150 mg every 12 hours 2
- Ages 6-11 years: 150 mg every 12 hours 3
- Ages 2-5 years: 50 mg (weight <14 kg) or 75 mg (weight ≥14 kg) every 12 hours 4
- Ages 12-24 months: 50 mg (weight 7 to <14 kg) or 75 mg (weight ≥14 to <25 kg) every 12 hours 5
Key Evidence for Ivacaftor:
The landmark Ramsey trial demonstrated that ivacaftor 150 mg twice daily in patients ≥12 years with G551D mutation resulted in 10.4% improvement in FEV₁ from baseline versus placebo at 24 weeks (P<0.001), 55% reduction in pulmonary exacerbations (P<0.001), and significant improvements in quality of life and nutritional status 2.
Important Caveats:
- Mutation-specific: Ivacaftor is effective for G551D and other gating mutations, but NOT effective for homozygous F508del mutations when used alone 2
- Liver monitoring required: Particularly in young children, as elevated transaminases (>8× ULN) occurred in 15% of children aged 2-5 years 4
- Drug interactions: Dose reduction required with strong CYP3A4 inhibitors (ritonavir increases exposure 7-fold) 6
Long-term Outcomes:
Real-world data over 8 years shows ivacaftor reduces mortality (HR 0.22), lung transplant rates (HR 0.11), and hospitalizations (rate ratio 0.50) while maintaining sustained improvements in lung function 7.